• Three Novel Candidates as Mu Opioid Receptor Antagonists: An In Silico Study
  • Maysam Fadaei-kenarsary,1 Alieh Ameri,2,*
    1. Institute of Neuropharmacology, Kerman Neuroscience Research Center, Kerman University of Medical Sciences
    2. Department of Medicinal Chemistry, Faculty of Pharmacy and Pharmaceutical Sciences, Kerman & Isfahan University of Medical Sciences


  • Introduction: Morphine analgesic overdose is a lethal condition that is reversible by administration of mu opioid antagonists like naloxone. This treatment can be associated with side effects. In this study we aimed to design novel chemical compounds as potential mu opioid receptor (MOR) antagonists.
  • Methods: We used Chemdraw, Hyperchem and Autodock Tools softwares to design, optimize and dock these compounds to the receptor. We designed 11 chemical compounds that 3 of them were successfully docked. None of these 3 compounds were found in Google scholar, Google search engine and other databases. Exclusion criteria included unsolved non-integral charge, half electron approximation in geometry with minimum energy, non-bonded atoms and optimization errors.
  • Results: The obtained results of the molecular docking simulation using the mu opioid receptor (PDB code: 4DKL) showed lowest binding energies (LBEs) and estimated Inhibition constants (KIs). Three novel compounds including a 8-Carboxamidocyclazocine analogue (LBE= -8.99 kcal/mol, Ki=256.85 nM) and two triazole derivatives (LBE= -9.21 kcal/mol, Ki=178.45 nM and LBE= -8.66 kcal/mol, Ki=445.88 nM) were suitably fitted in the active site of MOR in comparison with the main ligand (LBE=-10.13 kcal/mol, Ki=37.78 nM) in MOR. In parallel, LBEs and KIs of 3 novel compounds and standard antagonist naloxone (LBE=-8.21 kcal/mol, Ki=960.18 nM) in temperature of 298.15 K were compared.
  • Conclusion: As a conclusion, all of three novel compounds had better potential antagonist properties than standard antagonist naloxone. The best antagonist candidate among them was 7-amino-3-(cyclopropylmethyl)-6,11-dimethyl-1,2,3,4,5,6-hexahydro-2,6-methanobenzo[d]azocine-8-carboxamide. We suggest further In Silico, synthetic, In Vitro, In Vivo and behavioral studies to evaluate selectivity of these compounds to the MOR, their brain penetration, efficacy and safety as potential therapeutic drugs and antidotes in morphine dependence and overdose.
  • Keywords: Mu opioid receptor, Antagonist, Morphine, Naloxone, Molecular Docking Simulation